This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

UPC Düsseldorf refers Pfizer’s revocation counterclaim to Milan, continues infringement case

( March 4, 2025, 17:11 GMT | Official Statement) -- MLex Summary: The Unified Patent Court's Düsseldorf Local Division has ruled to refer Pfizer’s counterclaim for revocation of EP 4,183,412 to the UPC's Milan Central Division, as Pfizer had already filed a separate revocation action there last year. The court said the referral was also justified because both parties agreed to send the counterclaim to Milan. However, the court allowed GlaxoSmithKline’s infringement case to continue and granted Pfizer a one-month extension to submit its response, which is now due by April 13.The document is attached. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections